Driven by science, dedicated to service.
EPO is a preclinical contract research organization (CRO) founded in 1997 as a spin-off from the Max-Delbrück-Center for Molecular Medicine [MDC] in Berlin Buch. Since then, EPO has grown steadily and today has more than 450 customers worldwide, including large pharmaceutical and biotech firms and research laboratories from world-renowned universities and institutions. The company currently employs around 50 people, more than 20 of whom hold a PhD, and is led by Dr. Jens Hoffmann (CEO) and Prof. Dr. Wolfgang Walther (CSO). EPO is based in the Karl-Lohmann-Building on the Research Campus Berlin Buch with over 1300 m² (12.000 sqf) of laboratory space. The research campus Berlin-Buch is located in the north-east of Berlin and houses research institutes, hospitals and several biotech companies.
Based on its 25 years of experience, EPO is offering customized and comprehensive preclinical oncology and immuno-oncology services for the development of novel anti-cancer drugs. Our portfolio includes more than 600 well characterized PDX models of about 17 cancer entities (solid cancers, leukemia), cell line-derived xenograft- as well as syngeneic tumor models. Of note, EPO has long term experience in the establishment of humanized models and has been running studies in these for over a decade.
EPO´s highly qualified team guarantees short response and turnover times, flexible study design, regular updates and a transparent communication style. Our scientists are regularly authoring and co-authoring scientific papers published in prestigious, peer reviewed international journals and are presenting posters as well as oral presentations at national and international cancer conferences. Furthermore, EPO actively participates in several public-private research consortia such as the multicenter OncoTrack and the ITCC P4 project. Science is our passion and we provide services for scientists, by scientists.